

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Treprostinil sodium for treating symptomatic chronic thromboembolic pulmonary hypertension ID3926

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AOP Orphan (Treprostinil sodium) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Blood Pressure UK • British Cardiovascular Society • British Lung Foundation • Cardiovascular Care Partnership • Network of Sikh Organisations • Pulmonary Hypertension Association UK • Pumping Marvellous Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Thrombosis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British and Irish Hypertension Society • British Association for Nursing in Cardiovascular Care • British Geriatrics Society • British Heart Foundation • British Nuclear Cardiology Society • British Society for Haematology • British Society for Heart Failure • British Society of Cardiovascular Imaging • British Thoracic Society • National Heart and Lung Institute • Primary Care Cardiovascular Society • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society for Vascular Nurses • Society for Vascular Technology • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (ambrisentan, bosentan, sildenafil, tadalafil) • Advanz Pharma (bosentan, epoprostenol, sildenafil) • Almus Pharma (sildenafil) • Aristo Pharma (tadalafil) • Aspire Pharma (tadalafil) • Aurobindo Pharma – Milpharm (bosentan, sildenafil, tadalafil) • Bayer (iloprost) • Bristol Laboratories (sildenafil, tadalafil) • Cilpa EU (ambrisentan, bosentan tadalafil) • Colonis Pharma (iloprost) • Dr Reddy's Laboratories UK (ambrisentan, bosentan, sildenafil, treprostinil sodium) • Eli Lilly and Company (tadalafil)

Provisional stakeholder list for the single technology appraisal of treprostinil sodium for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926]

Issue date: November 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • Great Ormond Street Hospital for Children NHS Foundation Trust • Imperial College Healthcare NHS Trust • Newcastle upon Tyne Hospitals NHS Foundation Trust • NHS Bassetlaw CCG • NHS Doncaster CCG • NHS England • Royal Brompton and Harefield NHS Foundation Trust • Royal Free London NHS Foundation Trust • Royal Papworth Hospital NHS Foundation Trust • Sheffield Teaching Hospitals NHS Foundation Trust • Welsh Government 	<ul style="list-style-type: none"> • GlaxoSmithKline (ambrisentan, epoprostenol) • Janssen-Cilag (bosentan, epoprostenol, macitentan, selexipag) • Macleods Pharma UK (sildenafil) • Medreich (tadalafil) • Merck Sharp & Dohme (riociguat) • Noumed Life Sciences (tadalafil) • Sandoz (sildenafil) • Somex Pharma (sildenafil) • Sun Pharmaceuticals (epoprostenol, tadalafil) • Teva UK (sildenafil) • Tillomed Laboratories (treprostinil sodium) • Torrent Pharma (sildenafil) • Zentiva (ambrisentan, bosentan iloprost) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiac and Cardiology Research Dept, Barts • Circulation Foundation • Cochrane Heart Group • Cochrane Hypertension Group • Cochrane UK • Cochrane Vascular • European Council for Cardiovascular Research • Genomics England • Heart Research UK • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research • National Pulmonary Hypertension Audit • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Provisional stakeholder list for the single technology appraisal of treprostinil sodium for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926]

Issue date: November 2021

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.